NOVOCURE LTD (NVCR) Fundamental Analysis & Valuation

NASDAQ:NVCR • JE00BYSS4X48

Current stock price

10.36 USD
-0.61 (-5.56%)
At close:
10.36 USD
0 (0%)
After Hours:

This NVCR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. NVCR Profitability Analysis

1.1 Basic Checks

  • In the past year NVCR has reported negative net income.
  • NVCR had a negative operating cash flow in the past year.
  • NVCR had negative earnings in each of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: NVCR reported negative operating cash flow in multiple years.
NVCR Yearly Net Income VS EBIT VS OCF VS FCFNVCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M

1.2 Ratios

  • NVCR has a Return On Assets of -16.94%. This is comparable to the rest of the industry: NVCR outperforms 54.26% of its industry peers.
  • The Return On Equity of NVCR (-40.01%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -16.94%
ROE -40.01%
ROIC N/A
ROA(3y)-16.2%
ROA(5y)-12.3%
ROE(3y)-47.98%
ROE(5y)-35.83%
ROIC(3y)N/A
ROIC(5y)N/A
NVCR Yearly ROA, ROE, ROICNVCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • NVCR's Gross Margin of 74.73% is amongst the best of the industry. NVCR outperforms 84.57% of its industry peers.
  • NVCR's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for NVCR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.78%
GM growth 5Y-1.02%
NVCR Yearly Profit, Operating, Gross MarginsNVCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. NVCR Health Analysis

2.1 Basic Checks

  • NVCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NVCR has been increased compared to 1 year ago.
  • The number of shares outstanding for NVCR has been increased compared to 5 years ago.
  • The debt/assets ratio for NVCR has been reduced compared to a year ago.
NVCR Yearly Shares OutstandingNVCR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
NVCR Yearly Total Debt VS Total AssetsNVCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of 0.21, we must say that NVCR is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.21, NVCR is in line with its industry, outperforming 44.68% of the companies in the same industry.
  • NVCR has a Debt/Equity ratio of 0.57. This is a neutral value indicating NVCR is somewhat dependend on debt financing.
  • NVCR has a Debt to Equity ratio of 0.57. This is in the lower half of the industry: NVCR underperforms 60.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.57
Debt/FCF N/A
Altman-Z 0.21
ROIC/WACCN/A
WACC9.74%
NVCR Yearly LT Debt VS Equity VS FCFNVCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 2.90 indicates that NVCR has no problem at all paying its short term obligations.
  • NVCR has a Current ratio (2.90) which is comparable to the rest of the industry.
  • NVCR has a Quick Ratio of 2.71. This indicates that NVCR is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 2.71, NVCR is doing good in the industry, outperforming 60.64% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.9
Quick Ratio 2.71
NVCR Yearly Current Assets VS Current LiabilitesNVCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. NVCR Growth Analysis

3.1 Past

  • NVCR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.79%, which is quite impressive.
  • NVCR shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.28%.
  • The Revenue has been growing slightly by 5.80% on average over the past years.
EPS 1Y (TTM)21.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.93%
Revenue 1Y (TTM)8.28%
Revenue growth 3Y6.81%
Revenue growth 5Y5.8%
Sales Q2Q%8.11%

3.2 Future

  • Based on estimates for the next years, NVCR will show a very strong growth in Earnings Per Share. The EPS will grow by 43.12% on average per year.
  • The Revenue is expected to grow by 22.91% on average over the next years. This is a very strong growth
EPS Next Y-31.26%
EPS Next 2Y-2.41%
EPS Next 3Y11.76%
EPS Next 5Y43.12%
Revenue Next Year5.56%
Revenue Next 2Y6.15%
Revenue Next 3Y8.09%
Revenue Next 5Y22.91%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NVCR Yearly Revenue VS EstimatesNVCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
NVCR Yearly EPS VS EstimatesNVCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. NVCR Valuation Analysis

4.1 Price/Earnings Ratio

  • NVCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year NVCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NVCR Price Earnings VS Forward Price EarningsNVCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVCR Per share dataNVCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.41%
EPS Next 3Y11.76%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NVCR Dividend Analysis

5.1 Amount

  • NVCR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NVCR Fundamentals: All Metrics, Ratios and Statistics

NOVOCURE LTD

NASDAQ:NVCR (3/30/2026, 8:21:19 PM)

After market: 10.36 0 (0%)

10.36

-0.61 (-5.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-26
Earnings (Next)04-20
Inst Owners85.62%
Inst Owner Change6.81%
Ins Owners2.71%
Ins Owner Change2.11%
Market Cap1.18B
Revenue(TTM)655.35M
Net Income(TTM)-136.23M
Analysts81.54
Price Target26.45 (155.31%)
Short Float %8.9%
Short Ratio4.41
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.36%
Min EPS beat(2)23.15%
Max EPS beat(2)47.58%
EPS beat(4)4
Avg EPS beat(4)28.35%
Min EPS beat(4)8.12%
Max EPS beat(4)47.58%
EPS beat(8)7
Avg EPS beat(8)12.48%
EPS beat(12)9
Avg EPS beat(12)6%
EPS beat(16)11
Avg EPS beat(16)5.33%
Revenue beat(2)1
Avg Revenue beat(2)0.79%
Min Revenue beat(2)-1.4%
Max Revenue beat(2)2.98%
Revenue beat(4)3
Avg Revenue beat(4)1.55%
Min Revenue beat(4)-1.4%
Max Revenue beat(4)3.65%
Revenue beat(8)7
Avg Revenue beat(8)2.98%
Revenue beat(12)7
Avg Revenue beat(12)1.19%
Revenue beat(16)9
Avg Revenue beat(16)0.88%
PT rev (1m)2.83%
PT rev (3m)4.61%
EPS NQ rev (1m)5.99%
EPS NQ rev (3m)-31.02%
EPS NY rev (1m)-4.28%
EPS NY rev (3m)-5.1%
Revenue NQ rev (1m)13.51%
Revenue NQ rev (3m)-0.31%
Revenue NY rev (1m)1.49%
Revenue NY rev (3m)0.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.8
P/FCF N/A
P/OCF N/A
P/B 3.46
P/tB 3.46
EV/EBITDA N/A
EPS(TTM)-1.22
EYN/A
EPS(NY)-1.6
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS5.76
BVpS2.99
TBVpS2.99
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -16.94%
ROE -40.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.73%
FCFM N/A
ROA(3y)-16.2%
ROA(5y)-12.3%
ROE(3y)-47.98%
ROE(5y)-35.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.78%
GM growth 5Y-1.02%
F-Score3
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 0.57
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 181.9%
Cap/Sales 4.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.9
Quick Ratio 2.71
Altman-Z 0.21
F-Score3
WACC9.74%
ROIC/WACCN/A
Cap/Depr(3y)270.11%
Cap/Depr(5y)249.45%
Cap/Sales(3y)5.49%
Cap/Sales(5y)4.99%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.93%
EPS Next Y-31.26%
EPS Next 2Y-2.41%
EPS Next 3Y11.76%
EPS Next 5Y43.12%
Revenue 1Y (TTM)8.28%
Revenue growth 3Y6.81%
Revenue growth 5Y5.8%
Sales Q2Q%8.11%
Revenue Next Year5.56%
Revenue Next 2Y6.15%
Revenue Next 3Y8.09%
Revenue Next 5Y22.91%
EBIT growth 1Y11.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.25%
EBIT Next 3Y24.89%
EBIT Next 5Y56.67%
FCF growth 1Y-9.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-85.94%
OCF growth 3YN/A
OCF growth 5YN/A

NOVOCURE LTD / NVCR Fundamental Analysis FAQ

What is the fundamental rating for NVCR stock?

ChartMill assigns a fundamental rating of 3 / 10 to NVCR.


What is the valuation status of NOVOCURE LTD (NVCR) stock?

ChartMill assigns a valuation rating of 0 / 10 to NOVOCURE LTD (NVCR). This can be considered as Overvalued.


Can you provide the profitability details for NOVOCURE LTD?

NOVOCURE LTD (NVCR) has a profitability rating of 2 / 10.